Veeva Systems Inc. (NYSE: VEEV), a healthcare firm with a market capitalization of $10.3 billion, saw its share price increase by 30.7% over the prior three months. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. Is there still an opportunity here to buy? Let’s examine Veeva’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

What’s The Opportunity In Veeva?

Veeva appears to be overvalued by -34.0% at the moment, based on 8 separate valuation models. The stock is currently trading at $71.13 on the market compared to our average intrinsic value of $46.94. This means that the buying opportunity has probably disappeared for now.

Veeva Systems Inc Valuation Detail Analysis Model Fair Value Upside (Downside) 10-yr DCF Revenue Exit $49.95 -29.8% 5-yr DCF Revenue Exit $56.87 -20.0% Peer Revenue Multiples $42.61 -40.1% 10-yr DCF EBITDA Exit $44.51 -37.4% 5-yr DCF EBITDA Exit $48.24 -32.2% 10-yr DCF Growth Exit $41.12 -42.2% 5-yr DCF Growth Exit $43.60 -38.7% Peer P/E Multiples $48.65 -31.6% Average $46.94 -34.0%

Click on any of the analyses above to view the latest model with real-time data.

However, will there be another opportunity to buy low in the future? Given that Veeva’s stock is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) could mean the price can sink lower, giving investors another chance to buy in the future. This is based on its beta of 1.26, which is a good indicator for share price volatility.

Can We Expect Growth From Veeva?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matters the most, a more compelling investment thesis would be high growth potential at a cheap price.